基于专利视角的葡萄糖激酶激活剂研究分析  

Analysis of Glucokinase Activators Research from a Patent Perspective

作　　者：李璐 齐燕[2] 杜然然[2] 高东平[2] LI Lu;QI Yan;DU Ranran;GAO Dongping(Faculty of Data Science,City University of Macao,Macao 999078,China;Institute of Medical Information/Library,Chinese Academy of Medical Sciences,Beijing 100020,China)

机构地区：[1]澳门城市大学数据科学学院,中国澳门999078 [2]中国医学科学院医学信息研究所/图书馆,北京100020

出　　处：《世界科技研究与发展》2023年第S01期88-102,共15页World Sci-Tech R&D

基　　金：中国医学科学院医学与健康科技创新工程项目“小檗碱预防心脑血管及代谢性疾病的大规模多中心随机对照试验与相关机制研究”(2021-I2M-1-009)。

摘　　要：近年来,全球糖尿病患者数量高速增长,中国成人糖尿病患病率已经达到11.9%。药物是治疗糖尿病的重要手段之一,其中针对在肝细胞葡萄糖稳态调控中起核心作用的葡萄糖激酶这一靶点的葡萄糖激酶激活剂(GKA),是2型糖尿病新型药物研发的热点之一。科学分析葡萄糖激酶激活剂相关专利技术现状,能够为葡萄糖激酶激活剂相关产业发展提供科技情报支撑及决策参考。本文运用专利计量学方法,以德温特专利数据库和Cortellis数据库为数据源,对葡萄糖激酶激活剂相关专利的申请态势、专利分布区域、专利申请人及其药物、专利技术构成及其热点,以及技术发展路径等进行分析。结果表明,目前GKA技术仍在持续发展中,美国和日本是主要布局区域;在专利申请人方面,国外的罗氏公司、阿斯利康公司和辉瑞公司以及国内的华领医药公司申请数量较多;专利技术热点涉及药物结构、药物剂型、药物配伍、药物化学、疾病治疗等七个方面。最后,基于分析结果对我国葡萄糖激酶激活剂领域提出建议,以期为未来专利的申请布局以及产品创新研发等提供参考。In recent years,there has been a rapid increase in the worldwide population of individuals with diabetes,and the prevalence of diabetes among adults in China has reached 11.9%.Medications play a pivotal role in the management of diabetes.Glucokinase activators(GKA)have garnered considerable attention in the research and development of novel medications for the treatment of type 2 diabetes,owing to their ability to target glucokinase,a key regulator of glucose homeostasis in hepatic cells.An examination of the current status of patents concerning glucokinase activators can offer valuable scientific and technological insights to inform decision-making and drive the progress of industries associated with glucokinase activators.This study utilizes the patent metrology method,drawing on the Derwent patent database and Cortellis database as primary data sources,to analyze patent application trends,patent distribution,patent applicants,their pharmaceutical products,patent technology composition,hotspots,and the technological development trajectory.The findings indicate that GKA technology is in a state of ongoing development,with the United States and Japan emerging as the main regions for its distribution.Roche,AstraZeneca,Pfizer,and Hualing Pharmaceutical Company have filed the highest number of patent applications.The patented technology encompasses seven key areas,including drug structure,drug dosage form,drug compatibility,pharmaceutical chemistry,and disease treatment.Based on the analysis results,several recommendations are put forward in the field of glucokinase activators in China,aiming to provide references for future patent application strategies and innovative product research and development.

关 键 词：葡萄糖激酶激活剂 GKA 专利分析 专利布局 

分 类 号：TQ460[化学工程—制药化工]